Prosensa
Provides RNA-based therapeutics for the treatment of genetic disorders, infections and cancers.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD1.1b (Public information from Nov 2014)
Company register number 28076693
Leiden South Holland (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
$18.0m | Series A | ||
$18.0m | Series B | ||
€30.0m | Late VC | ||
$23.0m | Late VC | ||
| N/A | N/A | IPO | |
$200k | Grant | ||
$680m Valuation: $680m | Acquisition | ||
| Total Funding | AUD142m | ||
